(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 September 2022 (29.09.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/201047 A1

(51) International Patent Classification:
A61K 35/17 (2015.01) *A61P 31/04* (2006.01)

(21) International Application Number:
PCT/IB2022/052636

(22) International Filing Date:
23 March 2022 (23.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/CN2021/082447 23 March 2021 (23.03.2021) CN
21169770.1 22 April 2021 (22.04.2021) EP

(71) Applicant: **GUIZHOU SINORDA BIOTECHNOLOGY CO., LTD.** [CN/CN]; Floor 13, Tower 3, Western China R&D Camp National Hi-tech Park, Guiyang, Guizhou 550008 (CN).

(72) Inventors: **YANG, Yuan**; Guizhou Sinorda Biotechnology Co., Ltd., Floor 12, Tower 3, Western China R&D Camp National Hi-tech Park, No. 28 Yang Guan Road, Guanshan Hu, Guanshan Hu, Guizhou 550008 (CN). **TANG, Jingling**; Guizhou Sinorda Biotechnology Co., Ltd., Floor 13, Tower 3, Western China R&D Camp National Hi-tech Park, No. 28 Yang Guan Road, Guanshan Hu, Guizhou 550008 (CN). **HU, Pingsheng**; Guizhou Sinorda Biotechnology Co., Ltd., Floor 13, Tower 3, Western China R&D Camp National Hi-tech Park, No. 28 Yang Guan Road, Guanshan Hu, Guizhou 550008 (CN). **LI, Xiaoyang**; Guizhou Sinorda Biotechnology Co., Ltd., Floor 13, Tower 3, Western China R&D Camp National Hi-tech Park, No. 28 Yang Guan Road, Guanshan Hu, Guizhou 550008 (CN). **WU, Liyun**; Guizhou Sinorda Biotechnology Co., Ltd., Floor 13, Tower 3, Western China R&D Camp National Hi-tech Park, No. 28 Yang Guan Road, Guanshan Hu, Guizhou 550008 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2022/201047 A1

(54) Title: NEW TREATMENT OF SEPSIS

(57) Abstract: The present invention relates to a method for treatment of sepsis in a subject comprising administering a pharmaceutical composition comprising an effective amount of allogeneic Natural Killer cells to said subject, and to methods for predicting a subject's susceptibility to such method of treatment.